Your browser doesn't support javascript.
loading
Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.
Nkrumah, F K; Osei-Kwasi, M; Dunyo, S K; Koram, K A; Afari, E A.
Afiliación
  • Nkrumah FK; Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana, Legon, Ghana.
Bull World Health Organ ; 76(4): 353-9, 1998.
Article en En | MEDLINE | ID: mdl-9803586
ABSTRACT
PIP: The seroresponse of standard-dose heat-stable AIK-C measles vaccine administered to infants at 6 months of age was compared to that of standard-dose Schwarz vaccine administered at 9 months of age in a measles-endemic area in West Africa. The study was conducted in Asamankese, the capital town of Ghana's East Akim District. Infants 24-27 weeks of age who had been attending the Asamankese maternal-child health clinic regularly and had received all the required immunizations were enrolled and randomly assigned to receive the AIK-C (n = 184) or the Schwarz (n = 193) vaccine. No severe adverse reactions were reported during the 10-day follow-up period in either vaccine group. In the AIK-C group, 96.9% of infants who were seronegative at preimmunization and 79.4% of those with preexisting antibodies had seroconverted by 3 months after immunization; at 6 months after immunization, these rates were 97.3% and 100%, respectively. In the Schwarz group, 98.2% of infants seronegative at immunization and 100% of those with preexisting antibodies seroconverted by 3 months after immunization; at 6 months, these rates were 99.1% and 80%, respectively. Although the geometric mean titres achieved were significantly higher in the Schwarz vaccine group, these titres were above the protective level of 200 mIU in the AIK-C group. Administration of measles vaccine at a younger age may be more easily incorporated into current Expanded Program on Immunization schedules.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacuna Antisarampión / Enfermedades Endémicas / Sarampión Tipo de estudio: Clinical_trials / Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Bull World Health Organ Año: 1998 Tipo del documento: Article País de afiliación: Ghana Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacuna Antisarampión / Enfermedades Endémicas / Sarampión Tipo de estudio: Clinical_trials / Diagnostic_studies / Evaluation_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Infant / Male País/Región como asunto: Africa Idioma: En Revista: Bull World Health Organ Año: 1998 Tipo del documento: Article País de afiliación: Ghana Pais de publicación: Suiza